An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Trial Profile

An Open-label, Randomized Cross-over, Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of Two Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Paclitaxel (Primary) ; HM 30181A
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors Athenex
  • Most Recent Events

    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Status changed from recruiting to completed, as per results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 12 Jun 2014 Status changed from planning to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top